Disease or Syndrome
Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce
Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.
Zevra Therapeutics Secures FDA Approval for Miplyffa, a Breakthrough Treatment for Niemann-Pick Disease Type C
Zevra Therapeutics, Miplyffa, FDA Approval, Niemann-Pick Disease Type C, Rare Lysosomal Storage Disorder, Arimoclomol
Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market
Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry
Sanofi Prepares for Regulatory Submission of Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib, BTK inhibitor, Multiple sclerosis, Non-relapsing secondary progressive multiple sclerosis (nrSPMS), Sanofi, HERCULES study, GEMINI 1 and 2 studies, Regulatory approval
Edgewise Therapeutics Sees 50% Stock Surge Following Positive Safety Data for Heart Disease Drug EDG-7500
Edgewise Therapeutics, EDG-7500, Heart Disease, Cardiomyopathy, Stock Surge, Safety Data, Camzyos Rival
Novo Nordisk’s CB1 Drug Monlunabant Shows Weight Loss Potential, but Raises Efficacy and Safety Concerns
Novo Nordisk, Monlunabant, CB1 receptor, obesity treatment, weight loss, efficacy, safety concerns, neuropsychiatric side effects
Pioneers in Obesity Treatment: Lasker Award Honors Scientists Behind GLP-1 Drugs
Lasker Award, GLP-1 drugs, obesity treatment, Joel Habener, Svetlana Mojsov, Lotte Bjerre Knudsen, medical research, pharmaceuticals.
Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream
Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis
Vanda Pharmaceuticals Receives FDA Rejection for Gastroparesis Treatment, Criticizes Agency’s Decision
Vanda Pharmaceuticals, FDA rejection, gastroparesis treatment, tradipitant, conclusory refusal